Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
CHEMET - succimer capsules
Product / population
CHEMET oral succimer for its pediatric lead-poisoning indication; not prophylaxis or treatment of lead encephalopathy.
Renal method
Qualitative renal impairment; no numeric clearance threshold supplied
Source revision
9/2024
Retrieved
2026-09-10
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Removal of drug is not equivalent to removal of lead chelates
The selected official and mirror sections distinguish drug dialyzability from chelate removal.
What to reconcile: Keep toxicology assessment and monitoring attached. Do not derive a dialysis supplement from removal information alone.
DailyMed / Recordati Rare Diseases Inc. · CHEMET oral succimer for its pediatric lead-poisoning indication; not prophylaxis or treatment of lead encephalopathy.
Monitoring or renal-toxicity guidance. This finding concerns risk or surveillance; it may not establish a dose adjustment.
Dialysis evidence: Removal information only - not a dialysis regimen
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The full prescribing-information renal subsection (8.5) supports baseline and periodic renal assessment during prolonged therapy, adequate hydration, and closer monitoring with a renal-impairment history. It distinguishes limited evidence of succimer dialyzability from non-dialyzability of lead chelates.
No clearance-band reduction or dialysis supplement is established by this paragraph. CBC/neutrophil and hepatic monitoring remain separate treatment safeguards. Follow the full renal subsection heading rather than relying solely on a highlights cross-reference.
RDM58-official-succimer-chemet-0082c53ab7-C1 · Source locator: Full PI 8.5 (Renal Impairment); sections 2.1 and 5.2-5.3
Source-specific limits
Selected sections only; not a complete prescribing monograph or independent clinician approval.
Exact DailyMed HTML identity and named sections read. Raw SPL XML, original document hash and complete revision history were not obtained. Availability is not established by label retrieval.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.